A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.

Whatever specific shape work takes in the near and distant future, it’s likely the COVID-19 era will be looked back upon as a before-and-after dividing line.

Clarius Mobile Health of Vancouver, B.C., has won FDA approval to market an AI model that works with the company’s handheld point-of-care ultrasound devices to identify and measure tendons of the foot, ankle and knee.

Instagram is a fairly close second, Facebook a fighting third, Twitter a respectable fourth and LinkedIn a visible fifth.

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company. 

The FDA has cleared U.K.-based Adaptix to market a 3D X-ray system that, according to the company, images hands, feet and elbows “at a fraction of the radiation dose and per-study cost of traditional CT.”

GE HealthCare has some favorable tailwinds at its back as it proceeds into its first year unattached to a certain venerable parent corporation. 

The latest findings highlight the worsening crisis of burnout among U.S. clinicians, who have frequently cited the COVID-19 pandemic as a major impact.